ArticleFrontiers in oncology2023

An alternative dosing strategy for ropeginterferon alfa-2b may help improve outcomes in myeloproliferative neoplasms: An overview of previous and ongoing studies with perspectives on the future.

Albert Qin et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.